Safety, Efficacy of Eglandin® in Living Donor Liver Transplanted Patient (PROVISION)
Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate superiority of Eglandin® (Alprostadil) 720㎍compared
to 360㎍ in terms of safety, efficacy in living donor liver transplant patient, peak AST
levels followed by Eglandin administration were assessed.